|
Gene: PCDH15 |
Gene summary for PCDH15 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PCDH15 | Gene ID | 65217 |
Gene name | protocadherin related 15 | |
Gene Alias | CDHR15 | |
Cytomap | 10q21.1 | |
Gene Type | protein-coding | GO ID | GO:0001894 | UniProtAcc | A2A3D8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
65217 | PCDH15 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.49e-04 | 2.17e-01 | 0.0155 |
65217 | PCDH15 | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.68e-05 | 3.20e-01 | -0.1808 |
65217 | PCDH15 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.58e-09 | 4.70e-01 | -0.0811 |
65217 | PCDH15 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.33e-07 | 4.35e-01 | -0.1088 |
65217 | PCDH15 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.64e-04 | 2.29e-01 | -0.1954 |
65217 | PCDH15 | HTA11_2112_2000001011 | Human | Colorectum | SER | 4.35e-04 | 4.60e-01 | -0.2196 |
65217 | PCDH15 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.46e-04 | 2.69e-01 | -0.1207 |
65217 | PCDH15 | HTA11_83_2000001011 | Human | Colorectum | SER | 4.11e-03 | 2.51e-01 | -0.1526 |
65217 | PCDH15 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.34e-05 | 2.53e-01 | -0.1464 |
65217 | PCDH15 | HTA11_866_2000001011 | Human | Colorectum | AD | 5.20e-03 | 1.20e-01 | -0.1001 |
65217 | PCDH15 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.44e-06 | 2.84e-01 | -0.059 |
65217 | PCDH15 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.02e-04 | 4.24e-01 | -0.1706 |
65217 | PCDH15 | HTA11_4255_2000001011 | Human | Colorectum | SER | 7.31e-40 | 2.65e+00 | 0.0446 |
65217 | PCDH15 | HTA11_9408_2000001011 | Human | Colorectum | AD | 2.11e-28 | 1.62e+00 | 0.0451 |
65217 | PCDH15 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.00e-24 | 2.19e+00 | 0.0131 |
65217 | PCDH15 | HTA11_10623_2000001011 | Human | Colorectum | AD | 3.93e-54 | 2.86e+00 | -0.0177 |
65217 | PCDH15 | HTA11_6801_2000001011 | Human | Colorectum | SER | 2.00e-25 | 2.35e+00 | 0.0171 |
65217 | PCDH15 | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.51e-59 | 1.94e+00 | 0.0338 |
65217 | PCDH15 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.81e-79 | 2.00e+00 | 0.0674 |
65217 | PCDH15 | HTA11_6818_2000001011 | Human | Colorectum | AD | 8.89e-54 | 2.92e+00 | 0.0112 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0060249 | Colorectum | AD | anatomical structure homeostasis | 94/3918 | 314/18723 | 9.37e-05 | 1.42e-03 | 94 |
GO:0001894 | Colorectum | AD | tissue homeostasis | 81/3918 | 268/18723 | 1.96e-04 | 2.62e-03 | 81 |
GO:00018941 | Colorectum | SER | tissue homeostasis | 66/2897 | 268/18723 | 5.87e-05 | 1.37e-03 | 66 |
GO:00602491 | Colorectum | SER | anatomical structure homeostasis | 74/2897 | 314/18723 | 1.01e-04 | 2.13e-03 | 74 |
GO:00602492 | Colorectum | MSS | anatomical structure homeostasis | 84/3467 | 314/18723 | 1.87e-04 | 2.64e-03 | 84 |
GO:00018942 | Colorectum | MSS | tissue homeostasis | 72/3467 | 268/18723 | 4.53e-04 | 5.40e-03 | 72 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PCDH15 | SNV | Missense_Mutation | c.1177G>A | p.Glu393Lys | p.E393K | protein_coding | tolerated(0.2) | probably_damaging(0.992) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | ||
PCDH15 | SNV | Missense_Mutation | novel | c.1753G>A | p.Ala585Thr | p.A585T | protein_coding | tolerated(0.25) | probably_damaging(0.997) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
PCDH15 | SNV | Missense_Mutation | c.4926N>C | p.Lys1642Asn | p.K1642N | protein_coding | tolerated_low_confidence(0.33) | benign(0.031) | TCGA-EK-A2H1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cetuximab | SD | ||
PCDH15 | SNV | Missense_Mutation | c.4112G>C | p.Arg1371Thr | p.R1371T | protein_coding | tolerated(0.18) | probably_damaging(0.988) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
PCDH15 | SNV | Missense_Mutation | novel | c.4597N>A | p.Glu1533Lys | p.E1533K | protein_coding | benign(0.003) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | ||
PCDH15 | SNV | Missense_Mutation | rs867920472 | c.2455N>A | p.Asp819Asn | p.D819N | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
PCDH15 | SNV | Missense_Mutation | c.5104G>C | p.Glu1702Gln | p.E1702Q | protein_coding | deleterious_low_confidence(0.02) | benign(0.371) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
PCDH15 | SNV | Missense_Mutation | rs751941551 | c.2554N>A | p.Asp852Asn | p.D852N | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-UC-A7PG-06 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
PCDH15 | SNV | Missense_Mutation | novel | c.3412G>A | p.Glu1138Lys | p.E1138K | protein_coding | deleterious(0.04) | possibly_damaging(0.885) | TCGA-VS-A8QA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
PCDH15 | SNV | Missense_Mutation | c.5362N>T | p.Pro1788Ser | p.P1788S | protein_coding | tolerated_low_confidence(0.53) | benign(0.009) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |